Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15301119 | 0.99 | BACE1 (0.48) | BACE1NUDT1KMT2ATBXA2RTP53 | |
| SCHEMBL23100601 | 0.89 | SMN1; SMN2 (0.43) | BACE1NUDT1KMT2ATP53MAPT | |
| SCHEMBL9979854 | 0.88 | BACE1 (0.54) | BACE1NUDT1KMT2ATBXA2RTP53 | |
| SCHEMBL23100606 | 0.88 | MAPT (0.53) | BACE1NUDT1KMT2ATBXA2RTP53 | |
| SCHEMBL23100636 | 0.86 | BACE1 (0.63) | BACE1NUDT1KMT2ATBXA2RTP53 | |
| SCHEMBL15908540 | 0.86 | AGTR1 (0.41) | KMT2ATBXA2RJAK2JAK1TYK2 | |
| SCHEMBL22777751 | 0.84 | BACE1 (0.50) | BACE1NUDT1KMT2ATBXA2RTP53 | |
| SCHEMBL28189725 | 0.84 | BACE1 (0.47) | BACE1NUDT1KMT2ATBXA2RJAK2 | |
| SCHEMBL15415539 | 0.84 | BACE1 (0.47) | BACE1NUDT1KMT2ATBXA2RSMN1; SMN2 | |
| SCHEMBL7741401 | 0.81 | MEN1 (0.59) | KMT2ATP53MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114728937-A | Compositions and methods for treating respiratory syncytial virus | 奇达拉治疗公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-2651903-B1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| EP-2651903-B1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| US-20150166533-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166533-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (US) | 2015-06-18 | — | — | US | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| US-8865705-B2 | Benzimidazole respiratory syncytial virus inhibitors | JANSSEN R&D IRELAND (IE) | 2014-10-21 | — | — | US | disclosed |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080446-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN R&D IRELAND (IE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267508-A1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | SBDS, CHUK, HAT1 | BACE1 858/4885NUDT1 180/4885KMT2A 890/4885 |
| US-20150166533-A1 | NOVEL 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, SARS1 | BACE1 2500/4885NUDT1 760/4885KMT2A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.